Section Arrow
TARS.NASDAQ
- Tarsus Pharmaceuticals
Quotes are at least 15-min delayed:2024/12/25 01:19 EST
Last
 54.04
-0.37 (-0.68%)
Day High 
54.88 
Prev. Close
54.41 
1-M High
56.77 
Volume 
128.79K 
Bid
53.28
Ask
56
Day Low
53.66 
Open
54.88 
1-M Low
47.63 
Market Cap 
2.08B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 52.34 
20-SMA 51.49 
50-SMA 46.58 
52-W High 56.77 
52-W Low 18.99 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.75/-1.25
Enterprise Value
2.11B
Balance Sheet
Book Value Per Share
6.21
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
17.45M
Operating Revenue Per Share
0.33
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.3853-0.0178-4.42%-- 
CMNDClearmind Medicine1.72+0.5+40.98%0.16PE
CEROCERo Therapeutics Holdings0.0623+0.0118+23.37%-- 
ATNF180 Life Sciences Corp2.9+1.03+55.08%0.23PE
RXRXRecursion Pharmaceuticals7.24+0.25+3.58%-- 
Quotes are at least 15-min delayed:2024/12/25 01:19 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.